Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Smart drugs take on rare salivary gland cancer in new trial

NCT ID NCT05408845

Disease control Sponsor: NRG Oncology Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Aug 18, 2026 · Updated 3 times

Summary

This phase II trial is testing whether newer targeted drugs (trastuzumab emtansine and trastuzumab deruxtecan) work better than standard chemotherapy plus trastuzumab for people with HER2-positive or HER2-low salivary gland cancer that has come back, spread, or cannot be removed. About 146 participants will be enrolled. The goal is to see if these antibody-drug conjugates can slow tumor growth or shrink tumors more effectively.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan, along with docetaxel chemotherapy
What this could lead to
If successful, this trial could point toward more effective, targeted treatment options for people with HER2-positive or HER2-low salivary gland cancer that has spread or cannot be removed.
What could go wrong
This is a mid-stage (phase II) trial with 146 participants, so results are not definitive. The newer drugs may not work better than standard therapy, and side effects from the chemotherapy-linked antibodies can be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 146 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2023

Expected to finish

Jul 2032

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Pathologically (histologically or cytologically) proven diagnosis of HER2-positive OR HER2-low expressing recurrent/metastatic salivary gland cancer (SGC) * HER2-positive cohort: * Note: The majority of HER2-positive SGCs are salivary duct carcinoma (SDCs), but to a lesser extent, other SGC subtypes can be HER2-positive (e.g., adenocarcinomas, mucoepidermoid carcinomas, etc.) and are eligible to be included on the study. Additionally, pathologists may sign out SDCs under other descriptors (e.g., ex-pleomorphic adenoma, adenocarcinoma), and these would be eligible if they are HER2-positive. * Note: HER2 evaluation based on local site immunohistochemistry (IHC), fluorescent in-situ hybridization (FISH), or local/commercial next-generation sequencing (NGS) is required. Any one of the following criteria observed in a primary tumor or metastasis would meet the study definition for "HER2-positive": * Immunohistochemistry (IHC) (3+) per the College of American Pathologists (CAP) breast cancer guidelines * Gene amplification by FISH (HER2/CEP17 ratio \>= 2.0) * Gene amplification by NGS (fold change \>= 2) * HER2-low expressing cohort: * Note: Local HER2 evaluation by immunohistochemistry (IHC) or fluorescent in-situ hybridization (FISH) is required. Any one of the following criteria observed in a primary tumor or metastasis would meet the study definition for "HER2-low": * IHC 1+ per the College of American Pathologists (CAP) breast cancer guidelines * IHC 2+ without evidence of amplification by FISH * Patients with unresectable disease who are not candidates for curative surgery or radiation OR recurrent OR metastatic disease that is evident on radiologic imaging * Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression * Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are eligible if the treating physician determines that immediate CNS specific treatment is not required and is unlikely to be required during the first cycle of therapy * HER2-positive cohort: Measurable or non-measurable disease by the RECIST v1.1 criteria. HER2-low expressing cohort: Measurable disease by the RECIST v1.1 criteria * History/physical examination within 30 days prior to registration * The following imaging within 60 days prior to registration: * CT or MRI of the neck (diagnostic quality with contrast, unless contraindicated) AND * CT scan of the chest (diagnostic quality with contrast, unless contraindicated) AND * If clinically indicated, CT or MRI of the abdomen and pelvis (diagnostic quality with contrast, unless contraindicated) * Age \>= 18 * Left ventricular ejection fraction (LVEF) \>= 50% assessed by echocardiogram or multigated acquisition (MUGA) scan within 30 days prior to registration * Zubrod (Eastern Cooperative Oncology Group \[ECOG\]) Performance Status of 0-2 within 14 days prior to registration * Absolute neutrophil count (ANC) \>= 1,500 cells/mm\^3 (within 14 days prior to registration) * Platelets \>= 100,000 cells/mm\^3 (within 14 days prior to registration) * Hemoglobin \>= 9.0 g/dL (within 14 days prior to registration) * HER2-positive cohort: Note: The use of transfusion or other intervention to achieve hemoglobin \[Hgb\] \>= 9.0 g/dL is acceptable * HER2-low expressing cohort: Note: Transfusion (red blood cell or platelet) or granulocyte-colony stimulating factor (granulocyte colony-stimulating factor \[G-CSF\]) is not allowed * Serum creatinine =\< 1.5 x upper limit of normal (ULN) OR calculated creatinine clearance (CrCl) \>= 30 mL/min by the Cockcroft-Gault formula (within 14 days prior to registration) * HER2-positive cohort: Total bilirubin =\< 1.5 x ULN (within 14 days prior to registration) (Not applicable to patients with known Gilbert's syndrome) (within 14 days prior to registration) * HER2-positive cohort: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\< 1.5 x ULN (within 14 days prior to registration) * HER2-low expressing cohort: Total bilirubin ≤ 1.5 x ULN if no liver metastases; or \< 3 x ULN in the presence of documented Gilbert's Syndrome or liver metastases (within 14 days prior to registration) (within 14 days prior to registration) * HER2-low expressing cohort: AST and ALT ≤ 3 x ULN if no liver metastases; or \< 5 x ULN with liver metastases (within 14 days prior to registration) * HER2-low expressing cohort: Serum albumin ≥ 2.5 g/dL (within 14 days prior to registration) * Known human immunodeficiency virus (HIV) infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months prior to registration are eligible for this trial. Testing is not required for entry into protocol * For patients with known evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated * Note: Known positive test for hepatitis B virus surface antigen (HBV sAg) indicating acute or chronic infection would make the patient ineligible unless the viral load becomes undetectable on suppressive therapy. Patients who are immune to hepatitis B (anti-hepatitis B surface antibody positive) are eligible (e.g., patients immunized against hepatitis B) * For patients with a known history of hepatitis C virus (HCV) infection, they must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load * Note: Known positive test for hepatitis C virus ribonucleic acid (HCV RNA) indicating acute or chronic infection would make the patient ineligible unless the viral load becomes undetectable on suppressive therapy * Negative urine or serum pregnancy test (in persons of childbearing potential) within 14 days prior to registration. Childbearing potential is defined as any person who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal * Willing to use highly effective contraceptives for participants of childbearing potential (participants who may become pregnant or who may impregnate a partner) during therapy and for 7 months following last dose of study drug; this inclusion is necessary because the treatment in this study may be significantly teratogenic. Women must refrain from donating eggs during this same period * Men with partners of childbearing potential must be willing to use a highly effective form of non-hormonal contraception or two effective forms of non-hormonal contraception by the patient and/or partner, and to continue the use of contraception for the duration of study treatment and for at least 7 months after the last dose of study treatment. Male patients whose partners are pregnant should use condoms for the duration of the pregnancy. Men must refrain from donating sperm during this same period * Prior to registration, patients who have had chemotherapy or palliative-intent radiotherapy must have all toxicities related to prior treatment recovered to ≤ grade 1 * Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial * The patient or a legally authorized representative must provide study-specific informed consent prior to study entry and, for patients treated in the United States (U.S.), authorization permitting release of personal health information Exclusion Criteria: * HER2-positive cohort: Prior systemic therapy for the study cancer in the unresectable or recurrent and/or metastatic disease setting * Note: Prior chemotherapy for a different cancer is allowed; prior androgen receptor targeted therapy in any setting is allowed; prior systemic therapy, including HER2-directed therapies given as neoadjuvant therapy, adjuvant therapy, and/or concurrently with radiation is allowed * HER2-low expressing cohort: HER2 directed therapy for unresectable or recurrent or metastatic disease is not allowed * Severe, active co-morbidity defined as follows: * Unstable angina requiring hospitalization in the last 6 months * Myocardial infarction within the last 6 months * New York Heart Association Functional Classification III/IV (Note: Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification.) * Persistent grade 3-4 (CTCAE version 5.0) electrolyte abnormalities that cannot be reversed despite replacement as indicated by repeat testing * Patient must not have an active infection requiring IV antibiotics, antivirals, or antifungals * HER2-positive cohort only: \>= grade 3 peripheral neuropathy * Interstitial lung disease or pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on chest CT scan * Any hemorrhage or bleeding event grade \>= 3 within 28 days prior to registration * History of allergic reactions to compounds of similar chemical or biologic composition to: HER2-positive cohort: ado-trastuzumab emtansine, trastuzumab, and/or docetaxel (or any of their excipients). HER2-low expressing cohort: DS-8201a (trastuzumab deruxtecan), trastuzumab * History of exposure to the following cumulative doses of anthracyclines: * Doxorubicin or liposomal doxorubicin \> 500 mg/m\^2 * Epirubicin \> 900 mg/m\^2 * Mitoxantrone \> 120 mg/m\^2 * Note: If another anthracycline, or more than one anthracycline has been used, the cumulative dose must not exceed the equivalent of doxorubicin 500 mg/m\^2 * HER2-low expressing cohort only: Receipt of live, attenuated vaccine (messenger ribonucleic acid \[mRNA and replication deficient adenoviral vaccines are not considered attenuated live vaccines) within 30 days prior to the first dose of DS-8201a (trastuzumab deruxtecan) * Pregnancy and individuals unwilling to discontinue nursing

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metastatic salivary gland carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

major salivary gland cancer major salivary gland carcinoma salivary gland cancer salivary gland carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metastatic salivary gland carcinoma Recurrent salivary gland carcinoma Stage III major salivary gland cancer ajcc V8 Stage IV major salivary gland cancer ajcc V8 Unresectable salivary gland carcinoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    144 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Abbott-Northwestern Hospital

    RECRUITING

    Minneapolis, Minnesota, 55407, United States

  • Arnold Palmer Cancer Center Medical Oncology Norwin

    RECRUITING

    N. Huntingdon, Pennsylvania, 15642, United States

    Contact Email: •••••@•••••

  • Boston Medical Center

    RECRUITING

    Boston, Massachusetts, 02118, United States

  • Broadlawns Medical Center

    RECRUITING

    Des Moines, Iowa, 50314, United States

  • Cancer Centers of Southwest Oklahoma Research

    RECRUITING

    Lawton, Oklahoma, 73505, United States

  • Carle Cancer Center

    RECRUITING

    Urbana, Illinois, 61801, United States

    Contact Email: •••••@•••••

  • Carle Physician Group-Effingham

    RECRUITING

    Effingham, Illinois, 62401, United States

    Contact Email: •••••@•••••

  • Carle Physician Group-Mattoon/Charleston

    RECRUITING

    Mattoon, Illinois, 61938, United States

    Contact Email: •••••@•••••

  • Carle at The Riverfront

    RECRUITING

    Danville, Illinois, 61832, United States

    Contact Email: •••••@•••••

  • Carlisle Regional Cancer Center

    RECRUITING

    Carlisle, Pennsylvania, 17015, United States

  • City of Hope Comprehensive Cancer Center

    ACTIVE_NOT_RECRUITING

    Duarte, California, 91010, United States

  • City of Hope at Irvine Lennar

    ACTIVE_NOT_RECRUITING

    Irvine, California, 92618, United States

  • Dartmouth Cancer Center - North

    SUSPENDED

    Saint Johnsbury, Vermont, 05819, United States

  • Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center

    RECRUITING

    Lebanon, New Hampshire, 03756, United States

  • Divine Providence Hospital

    RECRUITING

    Williamsport, Pennsylvania, 17754, United States

  • Emory University Hospital Midtown

    RECRUITING

    Atlanta, Georgia, 30308, United States

  • Fairview Southdale Hospital

    RECRUITING

    Edina, Minnesota, 55435, United States

  • Fred Hutchinson Cancer Center

    RECRUITING

    Seattle, Washington, 98109, United States

  • HaysMed

    RECRUITING

    Hays, Kansas, 67601, United States

  • Hennepin County Medical Center

    RECRUITING

    Minneapolis, Minnesota, 55415, United States

  • Huntsman Cancer Institute/University of Utah

    RECRUITING

    Salt Lake City, Utah, 84112, United States

    Contact Email: •••••@•••••

  • IRMC Cancer Center

    RECRUITING

    Indiana, Pennsylvania, 15701, United States

  • Iowa Methodist Medical Center

    RECRUITING

    Des Moines, Iowa, 50309, United States

  • Kaiser Permanente Downtown Commons

    RECRUITING

    Sacramento, California, 95814, United States

  • Kaiser Permanente Dublin

    RECRUITING

    Dublin, California, 94568, United States

  • Kaiser Permanente Fresno Orchard Plaza

    RECRUITING

    Fresno, California, 93720, United States

  • Kaiser Permanente Medical Center - Santa Clara

    RECRUITING

    Santa Clara, California, 95051, United States

  • Kaiser Permanente Moanalua Medical Center

    RECRUITING

    Honolulu, Hawaii, 96819, United States

  • Kaiser Permanente San Leandro

    RECRUITING

    San Leandro, California, 94577, United States

  • Kaiser Permanente- Modesto MOB II

    RECRUITING

    Modesto, California, 95356, United States

  • Kaiser Permanente-Fremont

    RECRUITING

    Fremont, California, 94538, United States

  • Kaiser Permanente-Fresno

    RECRUITING

    Fresno, California, 93720, United States

  • Kaiser Permanente-Modesto

    RECRUITING

    Modesto, California, 95356, United States

  • Kaiser Permanente-Oakland

    RECRUITING

    Oakland, California, 94611, United States

  • Kaiser Permanente-Roseville

    RECRUITING

    Roseville, California, 95661, United States

  • Kaiser Permanente-San Francisco

    RECRUITING

    San Francisco, California, 94115, United States

  • Kaiser Permanente-Santa Rosa

    RECRUITING

    Santa Rosa, California, 95403, United States

  • Kaiser Permanente-Santa Teresa-San Jose

    RECRUITING

    San Jose, California, 95119, United States

  • Kaiser Permanente-South Sacramento

    RECRUITING

    Sacramento, California, 95823, United States

  • Kaiser Permanente-South San Francisco

    RECRUITING

    South San Francisco, California, 94080, United States

  • Kaiser Permanente-Vallejo

    RECRUITING

    Vallejo, California, 94589, United States

  • Kaiser Permanente-Walnut Creek

    RECRUITING

    Walnut Creek, California, 94596, United States

  • Kaiser San Rafael-Gallinas

    RECRUITING

    San Rafael, California, 94903, United States

  • Lawrence Memorial Hospital

    RECRUITING

    Lawrence, Kansas, 66044, United States

  • Marshfield Medical Center - Minocqua

    RECRUITING

    Minocqua, Wisconsin, 54548, United States

    Contact Email: •••••@•••••

  • Marshfield Medical Center - Weston

    RECRUITING

    Weston, Wisconsin, 54476, United States

    Contact Email: •••••@•••••

  • Marshfield Medical Center-EC Cancer Center

    RECRUITING

    Eau Claire, Wisconsin, 54701, United States

    Contact Email: •••••@•••••

  • Marshfield Medical Center-Marshfield

    RECRUITING

    Marshfield, Wisconsin, 54449, United States

    Contact Email: •••••@•••••

  • Marshfield Medical Center-Rice Lake

    RECRUITING

    Rice Lake, Wisconsin, 54868, United States

    Contact Email: •••••@•••••

  • Marshfield Medical Center-River Region at Stevens Point

    RECRUITING

    Stevens Point, Wisconsin, 54482, United States

    Contact Email: •••••@•••••

  • Mayo Clinic in Rochester

    RECRUITING

    Rochester, Minnesota, 55905, United States

  • McFarland Clinic - Ames

    ACTIVE_NOT_RECRUITING

    Ames, Iowa, 50010, United States

  • Medical College of Wisconsin

    RECRUITING

    Milwaukee, Wisconsin, 53226, United States

  • Medical University of South Carolina

    RECRUITING

    Charleston, South Carolina, 29425, United States

  • Memorial Hospital East

    RECRUITING

    Shiloh, Illinois, 62269, United States

  • Memorial Sloan Kettering Basking Ridge

    RECRUITING

    Basking Ridge, New Jersey, 07920, United States

  • Memorial Sloan Kettering Bergen

    RECRUITING

    Montvale, New Jersey, 07645, United States

  • Memorial Sloan Kettering Cancer Center

    RECRUITING

    New York, New York, 10065, United States

  • Memorial Sloan Kettering Commack

    RECRUITING

    Commack, New York, 11725, United States

  • Memorial Sloan Kettering Monmouth

    RECRUITING

    Middletown, New Jersey, 07748, United States

  • Memorial Sloan Kettering Nassau

    RECRUITING

    Uniondale, New York, 11553, United States

  • Memorial Sloan Kettering Westchester

    RECRUITING

    Harrison, New York, 10604, United States

  • Mercy Hospital

    RECRUITING

    Coon Rapids, Minnesota, 55433, United States

  • Mercy Medical Center - Des Moines

    RECRUITING

    Des Moines, Iowa, 50314, United States

  • Miami Cancer Institute

    RECRUITING

    Miami, Florida, 33176, United States

  • Mount Sinai Chelsea

    ACTIVE_NOT_RECRUITING

    New York, New York, 10011, United States

  • Mount Sinai Hospital

    RECRUITING

    New York, New York, 10029, United States

  • Ohio State University Comprehensive Cancer Center

    RECRUITING

    Columbus, Ohio, 43210, United States

  • Park Nicollet Clinic - Saint Louis Park

    RECRUITING

    Saint Louis Park, Minnesota, 55416, United States

  • ProHealth D N Greenwald Center

    RECRUITING

    Mukwonago, Wisconsin, 53149, United States

  • ProHealth Oconomowoc Memorial Hospital

    RECRUITING

    Oconomowoc, Wisconsin, 53066, United States

  • Regions Hospital

    RECRUITING

    Saint Paul, Minnesota, 55101, United States

  • Saint Anthony Regional Hospital

    RECRUITING

    Carroll, Iowa, 51401, United States

  • Saint Luke's Cancer Institute - Boise

    RECRUITING

    Boise, Idaho, 83712, United States

  • Saint Luke's Cancer Institute - Fruitland

    RECRUITING

    Fruitland, Idaho, 83619, United States

  • Saint Luke's Cancer Institute - Meridian

    RECRUITING

    Meridian, Idaho, 83642, United States

  • Saint Luke's Cancer Institute - Nampa

    RECRUITING

    Nampa, Idaho, 83687, United States

  • Saint Luke's Cancer Institute - Twin Falls

    RECRUITING

    Twin Falls, Idaho, 83301, United States

  • Salina Regional Health Center

    RECRUITING

    Salina, Kansas, 67401, United States

  • Sanford Bismarck Medical Center

    RECRUITING

    Bismarck, North Dakota, 58501, United States

    Contact Email: •••••@•••••

  • Sanford Broadway Medical Center

    RECRUITING

    Fargo, North Dakota, 58122, United States

    Contact Email: •••••@•••••

  • Sanford Cancer Center Oncology Clinic

    RECRUITING

    Sioux Falls, South Dakota, 57104, United States

    Contact Email: •••••@•••••

  • Sanford Joe Lueken Cancer Center

    RECRUITING

    Bemidji, Minnesota, 56601, United States

    Contact Email: •••••@•••••

  • Sanford Roger Maris Cancer Center

    RECRUITING

    Fargo, North Dakota, 58122, United States

    Contact Email: •••••@•••••

  • Sanford USD Medical Center - Sioux Falls

    RECRUITING

    Sioux Falls, South Dakota, 57117-5134, United States

    Contact Email: •••••@•••••

  • Siteman Cancer Center at Christian Hospital

    RECRUITING

    St Louis, Missouri, 63136, United States

    Contact Email: •••••@•••••

  • Siteman Cancer Center at Saint Peters Hospital

    RECRUITING

    City of Saint Peters, Missouri, 63376, United States

    Contact Email: •••••@•••••

  • Siteman Cancer Center at West County Hospital

    RECRUITING

    Creve Coeur, Missouri, 63141, United States

    Contact Email: •••••@•••••

  • Siteman Cancer Center-South County

    RECRUITING

    St Louis, Missouri, 63129, United States

    Contact Email: •••••@•••••

  • Stanford Cancer Institute Palo Alto

    RECRUITING

    Palo Alto, California, 94304, United States

  • Swedish Cancer Institute-Issaquah

    RECRUITING

    Issaquah, Washington, 98029, United States

  • The Iowa Clinic PC

    RECRUITING

    West Des Moines, Iowa, 50266, United States

  • The University of Kansas Cancer Center - Olathe

    RECRUITING

    Olathe, Kansas, 66061, United States

    Contact Email: •••••@•••••

  • Trinity's Tony Teramana Cancer Center

    RECRUITING

    Steubenville, Ohio, 43952, United States

  • UCHealth Highlands Ranch Hospital

    RECRUITING

    Highlands Ranch, Colorado, 80129, United States

  • UCHealth University of Colorado Hospital

    RECRUITING

    Aurora, Colorado, 80045, United States

  • UCSF Medical Center-Mission Bay

    SUSPENDED

    San Francisco, California, 94158, United States

  • UI Health Care Mission Cancer and Blood - Ankeny Clinic

    RECRUITING

    Ankeny, Iowa, 50023, United States

  • UI Health Care Mission Cancer and Blood - Des Moines Clinic

    RECRUITING

    Des Moines, Iowa, 50309, United States

  • UI Health Care Mission Cancer and Blood - Laurel Clinic

    RECRUITING

    Des Moines, Iowa, 50314, United States

  • UI Health Care Mission Cancer and Blood - Waukee Clinic

    RECRUITING

    Waukee, Iowa, 50263, United States

  • UI Health Care Mission Cancer and Blood - West Des Moines Clinic

    RECRUITING

    Clive, Iowa, 50325, United States

  • UI Healthcare Mission Cancer and Blood - Fort Dodge

    RECRUITING

    Fort Dodge, Iowa, 50501, United States

    Contact Email: •••••@•••••

  • UPMC Altoona

    RECRUITING

    Altoona, Pennsylvania, 16601, United States

  • UPMC Camp Hill

    ACTIVE_NOT_RECRUITING

    Camp Hill, Pennsylvania, 17011, United States

  • UPMC Cancer Center at UPMC Horizon

    RECRUITING

    Farrell, Pennsylvania, 16121, United States

  • UPMC Cancer Center at UPMC McKeesport

    RECRUITING

    McKeesport, Pennsylvania, 15132, United States

  • UPMC Cancer Center at UPMC Northwest

    RECRUITING

    Seneca, Pennsylvania, 16346, United States

  • UPMC Cancer Center-Natrona Heights

    RECRUITING

    Natrona Heights, Pennsylvania, 15065, United States

  • UPMC Cancer Center-Uniontown

    RECRUITING

    Uniontown, Pennsylvania, 15401, United States

  • UPMC Cancer Center-Washington

    RECRUITING

    Washington, Pennsylvania, 15301, United States

  • UPMC Cancer Centers - Arnold Palmer Pavilion

    RECRUITING

    Greensburg, Pennsylvania, 15601, United States

  • UPMC Hillman Cancer Center - Monroeville

    RECRUITING

    Monroeville, Pennsylvania, 15146, United States

    Contact Email: •••••@•••••

  • UPMC Hillman Cancer Center - New Castle

    RECRUITING

    New Castle, Pennsylvania, 16105, United States

  • UPMC Hillman Cancer Center - Part of Frick Hospital

    RECRUITING

    Mount Pleasant, Pennsylvania, 15666, United States

  • UPMC Hillman Cancer Center - Passavant - Cranberry

    RECRUITING

    Cranberry Township, Pennsylvania, 16066, United States

  • UPMC Hillman Cancer Center Erie

    RECRUITING

    Erie, Pennsylvania, 16505, United States

    Contact Email: •••••@•••••

  • UPMC Hillman Cancer Center at Butler Health System

    RECRUITING

    Butler, Pennsylvania, 16001, United States

  • UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion

    RECRUITING

    Mechanicsburg, Pennsylvania, 17050, United States

  • UPMC Hillman Cancer Center in Coraopolis

    RECRUITING

    Moon Township, Pennsylvania, 15108, United States

  • UPMC Memorial

    RECRUITING

    York, Pennsylvania, 17408, United States

  • UPMC Pinnacle Cancer Center/Community Osteopathic Campus

    RECRUITING

    Harrisburg, Pennsylvania, 17109, United States

  • UPMC Western Maryland

    RECRUITING

    Cumberland, Maryland, 21502, United States

  • UPMC-Heritage Valley Health System Beaver

    RECRUITING

    Beaver, Pennsylvania, 15009, United States

  • UPMC-Johnstown/John P. Murtha Regional Cancer Center

    RECRUITING

    Johnstown, Pennsylvania, 15901, United States

  • UPMC-Mercy Hospital

    RECRUITING

    Pittsburgh, Pennsylvania, 15219, United States

  • UPMC-Passavant Hospital

    RECRUITING

    Pittsburgh, Pennsylvania, 15237, United States

  • UPMC-Saint Clair Hospital Cancer Center

    RECRUITING

    Pittsburgh, Pennsylvania, 15243, United States

  • UPMC-Saint Margaret

    RECRUITING

    Pittsburgh, Pennsylvania, 15215, United States

  • UW Cancer Center at ProHealth Care

    RECRUITING

    Waukesha, Wisconsin, 53188, United States

  • United Hospital

    RECRUITING

    Saint Paul, Minnesota, 55102, United States

  • University Health Truman Medical Center

    RECRUITING

    Kansas City, Missouri, 64108, United States

  • University of Alabama at Birmingham Cancer Center

    ACTIVE_NOT_RECRUITING

    Birmingham, Alabama, 35233, United States

  • University of Cincinnati Cancer Center-UC Medical Center

    RECRUITING

    Cincinnati, Ohio, 45219, United States

    Contact Email: •••••@•••••

  • University of Cincinnati Cancer Center-West Chester

    RECRUITING

    West Chester, Ohio, 45069, United States

    Contact Email: •••••@•••••

  • University of Kansas Cancer Center

    RECRUITING

    Kansas City, Kansas, 66160, United States

  • University of Kansas Cancer Center - Lee's Summit

    RECRUITING

    Lee's Summit, Missouri, 64064, United States

  • University of Kansas Cancer Center - North

    RECRUITING

    Kansas City, Missouri, 64154, United States

  • University of Kansas Cancer Center-Overland Park

    RECRUITING

    Overland Park, Kansas, 66210, United States

  • University of Kansas Health System Saint Francis Campus

    RECRUITING

    Topeka, Kansas, 66606, United States

  • University of Kansas Hospital-Indian Creek Campus

    RECRUITING

    Overland Park, Kansas, 66211, United States

  • University of Kansas Hospital-Westwood Cancer Center

    RECRUITING

    Westwood, Kansas, 66205, United States

  • University of Kentucky/Markey Cancer Center

    RECRUITING

    Lexington, Kentucky, 40536, United States

  • University of Michigan Rogel Cancer Center

    RECRUITING

    Ann Arbor, Michigan, 48109, United States

    Contact Email: •••••@•••••

  • University of New Mexico Cancer Center

    RECRUITING

    Albuquerque, New Mexico, 87106, United States

  • University of Oklahoma Health Sciences Center

    RECRUITING

    Oklahoma City, Oklahoma, 73104, United States

  • University of Pittsburgh Cancer Institute (UPCI)

    RECRUITING

    Pittsburgh, Pennsylvania, 15232, United States

  • VCU Massey Comprehensive Cancer Center

    RECRUITING

    Richmond, Virginia, 23298, United States

  • Vanderbilt University/Ingram Cancer Center

    RECRUITING

    Nashville, Tennessee, 37232, United States

  • Washington University School of Medicine

    RECRUITING

    St Louis, Missouri, 63110, United States

    Contact Email: •••••@•••••

  • Wayne State University/Karmanos Cancer Institute

    ACTIVE_NOT_RECRUITING

    Detroit, Michigan, 48201, United States

  • Weisberg Cancer Treatment Center

    ACTIVE_NOT_RECRUITING

    Farmington Hills, Michigan, 48334, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.